ESTERS FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISEASES Russian patent published in 2021 - IPC A61K9/08 A61K31/16 A61K31/201 A61K31/202 A61K31/203 A61P27/02 A61P27/04 

FIELD: medicine; ophthalmology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to ophthalmology, and is intended for the treatment of dry eye syndrome. The ophthalmic composition for the treatment, prevention or mitigation of symptoms of dry eye syndrome contains an ester of an anti-inflammatory lipoid mediator, which is the reaction product of an anti-inflammatory lipoid mediator and a polyol selected from polyethylene glycol, polyvinyl alcohol, inositol, sorbitol, xylitol, erythritol, as well as their combinations. The specified anti-inflammatory lipid mediator ester is selected from a group consisting of esterified polyunsaturated fatty acids selected from at least omega-3, at least omega-6 fatty acids or mixtures thereof. This composition also contains an ophthalmic water delivery system. In this case, the composition contains 10% by weight or less of the acidic form of the anti-inflammatory lipoid mediator. At least one omega-3 fatty acid is selected from a group consisting of alpha-linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapentaenoic acid, docohexaenoic acid (DHA), docozapentaenoic acid (DPA), tetracozapentaenoic acid, and tetracosahexaenoic acid (nisic acid), derivatives, metabolites, and mixtures thereof. At least one omega-6 fatty acid is selected from a group consisting of linoleic acid, gamma-linolenic acid (GLA), eicosadienoic acid, digomo-gamma-linolenic acid( DGLA), docosadienoic acid, adrenoic acid, docozapentaenoic acid, or a combination thereof. In another embodiment, a sterile preparation, containing the specified composition for injection into the eye or contact lens for the treatment, prevention or mitigation of the symptoms of dry eye syndrome in a patient in need thereof, is presented. In addition, a method for obtaining the specified ophthalmic composition and a method for treating, preventing or mitigating the symptoms of dry eye syndrome in a patient in need thereof are provided.

EFFECT: use of the group of inventions makes it possible to increase the effectiveness of the treatment, prevention or mitigation of symptoms of dry eye syndrome.

17 cl